Summary of the Conference Call for Guangdong Tianen Pharmaceutical Co., Ltd. Company Overview - Guangdong Tianen Pharmaceutical Co., Ltd. specializes in the research, production, and sales of pharmaceuticals, with key products including Hewei Zhengchang Wan, "Woliting" Lecithin Iodine Tablets, and "Aiting Jiu" Dapoxetine Hydrochloride Tablets. The company was established in 1999 and has developed a significant sales network over 20 years [3][3][3]. Key Points Discussed Employee Stock Ownership Plan - The company disclosed a draft for the 2026 Employee Stock Ownership Plan, aiming to raise a total of 33.608 million yuan, involving up to 145 participants including directors and core employees. The plan reflects management's confidence in future growth and the market potential of core business products [12][12][12]. Performance Targets - The performance assessment period for the employee stock plan is set from 2026 to 2028, with specific targets: - Revenue: 1 billion yuan in 2026, 1.5 billion yuan in 2027, and 2 billion yuan in 2028 - Profit: 300 million yuan in 2026, 500 million yuan in 2027, and 800 million yuan in 2028 [15][15][15]. Product Development and Approval - The company expects multiple core products to be approved or submitted for approval, including: - "Aiting Lie" Finasteride and Tadalafil Compound Capsules (first domestic generic) approved in December 2025 - Lidocaine and Prilocaine Aerosol (first domestic generic) nearing regulatory submission - Compound Sodium Sulfate Tablets (first domestic generic) expected approval in H1 2026 - Localization of Hewei Zhengchang Wan production expected to be approved in H1 2026 - Pilocarpine Eye Drops for presbyopia (first domestic generic) anticipated approval in H2 2026 [18][19][19]. Marketing and Sales Strategy - The company has initiated brand promotion efforts in key regions and expanded online sales through platforms like Douyin and JD.com. The localized production of Hewei Zhengchang Wan is expected to enhance sales, with good performance anticipated in Q1 and Q2 of the current year [20][20][20]. Alzheimer's Disease Research - The company is developing CKBA for Alzheimer's disease, focusing on a compound derived from traditional Chinese medicine. CKBA has shown promising results in animal models, demonstrating cognitive improvement and neuroprotection [21][22][22]. Future Product Launches - The company plans to enhance brand promotion and has established a dedicated team for third-party channels, including clinics and internet hospitals. The approval of Compound Sodium Sulfate Tablets will be followed by efforts to include it in medical insurance [23][24][24]. Clinical Trials for Skin Conditions - The company is prioritizing the registration of treatments for pediatric vitiligo and rosacea, with rosacea expected to progress faster due to its shorter treatment cycle. The market potential for rosacea is significant, with over 50 million patients in China [25][26][27]. International Market Exploration - The company aims to explore overseas markets for CKBA, particularly in the pediatric vitiligo segment, where there are currently no approved treatments. Plans to initiate IND applications with the FDA are underway [27][27][27]. Additional Notes - The conference highlighted the company's commitment to innovation and growth in the pharmaceutical sector, with a focus on integrating research, production, and sales [3][3][3]. - The management emphasized the importance of maintaining a robust pipeline of products and adapting to market needs through strategic marketing and sales initiatives [20][20][20].

Core Viewpoint - The announcement by Guangdong Tianen Pharmaceutical Co., Ltd. regarding the acceptance of the registration application for Lidocaine and Prilocaine aerosol marks a significant advancement in the research and commercialization of sexual health medications [1]. Group 1: Product Development - Tianen's subsidiary, Shandong Huabo Kaisheng Biotechnology Co., Ltd., received the acceptance notice from the National Medical Products Administration for the aerosol product [1]. - The original drug was developed by Plethora Solutions in the UK and has been commercially promoted in major European markets since 2013, transitioning from prescription to over-the-counter status in 2020 [1]. Group 2: Product Advantages - The aerosol formulation offers advantages over oral medications like Dapoxetine, including ease of use, higher patient compliance, rapid onset of action, and reduced side effects associated with oral drugs [1]. - The product has been validated through over ten years of clinical use in overseas markets, confirming its efficacy and safety [1]. Group 3: Market Positioning - Tianen has a strong brand foundation and channel advantages in the sexual health sector, with its core product "Aiting Jiu" (Dapoxetine) having established a comprehensive sales network [1]. - The successful launch of the aerosol could leverage the brand effect and channel resources of the "Aiting Jiu" series to quickly penetrate the market and enhance the company's competitive position in the sexual health business [2].

在产品管线方面，根据公司1月22日披露的公告显示，公司核心在研产品CKBA乳膏针对儿童白癜风的II 期临床试验申请已获得批准，前期探索性研究显示其联合光疗方案疗效显著，该II期试验计划于2026年 第一季度启动首例患者入组，并计划同期启动FDA临床申报。 与此同时，公司仿制药业务迎来收获期，根据公司2025年11月21日披露的投资者关系活动记录表显示， 公司复方硫酸钠片(国内首仿)与和胃整肠丸(国内独家)的本地化生产注册均预计在2026年上半年获批； 老花眼用药盐酸毛果芸香碱滴眼液(国内首仿)则预计在2026年下半年获批。 根据公告，本次员工持股计划的资金来源为员工合法薪酬及自筹资金，公司不存在向持有人提供财务资 助或为其贷款提供担保的情形。计划购买回购股份的价格为16.93元/股，拟持有的标的股票数量不超过 198.51万股，约占公司总股本的0.47%。 草案明确了2026年至2028年三个年度的业绩考核目标。2026年度，营业收入目标值为10.00亿元，触发 值为9.00亿元；考核利润目标值为3.00亿元，触发值为2.70亿元。2027年度，营业收入目标值提升至 15.00亿元，触发值为13.50亿元；考 ...

报告期内，公司核心板块两性健康业务受竞品数量持续增加，市场竞争激烈等因素导致销售收入有所下 滑，但已看到市场需求逐步回暖的趋势。公司的"爱廷玖"盐酸达泊西汀片具有较高的品牌护城河，公司 将持续加强品牌推广力度，促进"爱廷玖"的销售回升。同时，随着新品"爱廷列"非那雄胺他达拉非胶囊 的上市，预计两性健康板块后续将保持增长。 格隆汇1月28日丨泰恩康(301263.SZ)发布2025年度业绩预告，报告期内，归属于上市公司股东的净利润 2,500万元-3,500万元，同比减少67.66%-76.90%；扣除非经常性损益后的净利润2,700万元-3,700万元， 同比减少65.11%-74.54%。 报告期内，公司核心产品"和胃整肠丸"受制于泰国厂家产能不足以及进口到货不及预期等因素，导致其 销售收入有所下滑。公司正积极推进"和胃整肠丸"在国内的注册审批进程，力争尽快实现"和胃整肠 丸"在国内的生产落地，解决产能瓶颈。 ...

此外，2025年公司在坚持加大研发投入的同时，持续增加品牌推广的投入力度和深度，导致销售费用增 加，压缩了利润空间。 （文章来源：北京商报） 北京商报讯1月28日晚间，泰恩康（301263）发布2025年业绩预告显示，预计2025年实现归属净利润 2500万元至3500万元，比上年同期下降67.66%至76.9%。 泰恩康表示，报告期内，公司核心板块两性健康业务受竞品数量持续增加，市场竞争激烈等因素导致销 售收入有所下滑，但已看到市场需求逐步回暖的趋势。公司的"爱廷玖"盐酸达泊西汀片具有较高的品牌 护城河，公司将持续加强品牌推广力度，促进"爱廷玖"的销售回升。同时，随着新品"爱廷列"非那雄胺 他达拉非胶囊的上市，预计两性健康板块后续将保持增长。 同时，报告期内，公司核心产品"和胃整肠丸"受制于泰国厂家产能不足以及进口到货不及预期等因素， 导致其销售收入有所下滑。公司正积极推进"和胃整肠丸"在国内的注册审批进程，力争尽快实现"和胃 整肠丸"在国内的生产落地，解决产能瓶颈。 ...

泰恩康公告，预计2025年度净利润为2500万元-3500万元，同比下降67.66%-76.90%。报告期内，公司核 心板块两性健康业务受竞品数量持续增加，市场竞争激烈等因素导致销售收入有所下滑，但已看到市场 需求逐步回暖的趋势。公司的"爱廷玖"盐酸达泊西汀片具有较高的品牌护城河，公司将持续加强品牌推 广力度，促进"爱廷玖"的销售回升。同时，随着新品"爱廷列"非那雄胺他达拉非胶囊的上市，预计两性 健康板块后续将保持增长。 ...

南财智讯1月28日电，泰恩康发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为2500 万元—3500万元，同比预减67.66%—76.90%；预计2025年全年归属于上市公司股东的扣除非经常性损 益的净利润为2700万元—3700万元，同比预减65.11%—74.54%。业绩变动原因说明：（1）报告期内， 公司核心板块两性健康业务受竞品数量持续增加，市场竞争激烈等因素导致销售收入有所下滑，但已看 到市场需求逐步回暖的趋势。公司的"爱廷玖"盐酸达泊西汀片具有较高的品牌护城河，公司将持续加强 品牌推广力度，促进"爱廷玖"的销售回升。同时，随着新品"爱廷列"非那雄胺他达拉非胶囊的上市，预 计两性健康板块后续将保持增长。（2）报告期内，公司核心产品"和胃整肠丸"受制于泰国厂家产能不 足以及进口到货不及预期等因素，导致其销售收入有所下滑。公司正积极推进"和胃整肠丸"在国内的注 册审批进程，力争尽快实现"和胃整肠丸"在国内的生产落地，解决产能瓶颈。（3）2025年公司在坚持 加大研发投入的同时，持续增加品牌推广的投入力度和深度，导致销售费用增加，压缩了利润空间。 ...

Core Insights - 泰恩康 has been awarded the "ESG New Rising Bull Award Top 20" at the 2025 Sustainable Development Forum, indicating its commitment to sustainable practices in the pharmaceutical industry [1] - The company is focused on deepening its innovation strategy during the "14th Five-Year Plan" period, particularly in drug research and commercialization [1][4] R&D Progress - 泰恩康's subsidiary, 江苏博创园生物医药科技有限公司, received a notice from the National Medical Products Administration for a Phase II clinical trial application for CKBA cream in treating non-segmental vitiligo in children aged 2-12 [2] - The company successfully completed a Phase II clinical trial for CKBA in adults and plans to submit a Phase III application soon [2] - CKBA is a novel immune modulator derived from traditional Chinese medicine, showing potential for treating various immune-related diseases, including Alzheimer's [3][4] Clinical Development - 泰恩康 has initiated preclinical research for CKBA in treating Alzheimer's disease, with plans to submit an IND application by the second half of 2026 [4] - The company emphasizes the importance of innovation in drug development, aiming to provide solutions for Alzheimer's patients globally [4][6] Strategic Focus - 泰恩康 has transitioned to a research-driven model, increasing R&D investment from 6.9% to 21.96% of revenue between 2022 and 2024 [4] - The company employs a "pyramid" R&D strategy, focusing on generic drugs at the base, modified chemical drugs and biologics in the middle, and innovative drugs at the top [5][6] Product Structure - 泰恩康 has established three main product segments: sexual health, gastrointestinal, and ophthalmology, with notable products like "爱廷玖" and "和胃整肠丸" [6][7] - The company is expecting several core drugs to be approved soon, which will enhance its product structure and drive revenue growth [7]

Core Insights - The company, Taiankang, received the "ESG New Star Golden Bull Award Top 20" at the 2025 Golden Bull Enterprise Sustainable Development Forum, indicating its commitment to sustainable practices in the pharmaceutical industry [1] - During the 14th Five-Year Plan period, the company aims to deepen its focus on the pharmaceutical sector and implement an innovation-driven development strategy, enhancing its research and commercialization of innovative drugs [1][4] R&D Progress - Taiankang's subsidiary, Jiangsu Bochuangyuan Biopharmaceutical Technology Co., Ltd., received a notice from the National Medical Products Administration (NMPA) for the acceptance of its Phase II clinical trial application for CKBA cream in treating non-segmental vitiligo in children aged 2-12 [2] - The company successfully completed the Phase II clinical trial for CKBA in adult vitiligo patients and plans to submit a Phase III trial application soon [2] - CKBA is a novel immune modulator derived from traditional Chinese medicine, showing potential for treating other immune-related diseases, including Alzheimer's disease [3][4] Clinical Research and Development - The company has initiated preclinical research for CKBA in treating Alzheimer's disease, with plans to submit an Investigational New Drug (IND) application by the second half of 2026 [4] - CKBA has been recognized for its unique mechanism and potential in addressing Alzheimer's disease, which is increasingly prevalent due to aging populations [3][4] Innovation Strategy - Taiankang has established a comprehensive R&D system, focusing on various therapeutic areas, including dermatology, ophthalmology, and gastrointestinal health [5] - The company employs a "pyramid" R&D strategy, emphasizing innovative drug research at the top, supported by improved chemical drugs and biopharmaceuticals [6] - The company has transitioned from a sales-driven model to a research-driven approach, with R&D investment rising from 6.9% to 21.96% of revenue from 2022 to 2024 [4] Product Structure and Market Position - Taiankang has developed three main product segments: sexual health, gastrointestinal, and ophthalmic medications, with notable products like "Aiting Jiu" and "He Wei Zheng Chang Wan" [6][7] - The company is preparing to launch several core drugs, including domestic first generics, which are expected to enhance its product portfolio and drive revenue growth [7]

Core Viewpoint - 泰恩康 is committed to deepening its focus on the pharmaceutical industry and implementing an innovation-driven development strategy during the "14th Five-Year Plan" period, aiming to contribute more to the construction of a healthy China [1] R&D Progress - 泰恩康's subsidiary, Jiangsu Bochuangyuan Biopharmaceutical Technology Co., Ltd., received a notice from the National Medical Products Administration for the acceptance of a Phase II clinical trial application for CKBA cream in treating non-segmental vitiligo in children aged 2-12 [1][2] - The company successfully completed a Phase II clinical trial for CKBA in adult vitiligo and plans to submit a Phase III clinical trial application soon [2] - CKBA is a novel immune modulator derived from traditional Chinese medicine, showing targeted action and safety for treating pediatric vitiligo [2] Clinical Research and Potential - CKBA has shown significant potential in treating other immune-related diseases, including Alzheimer's disease, with research published in the journal Nature Aging [3] - 泰恩康 has initiated preclinical research for CKBA in Alzheimer's treatment, with plans to submit an IND application by the second half of 2026 [3] Innovation Development Strategy - 泰恩康 has transformed its business model from a sales-production-research model to a research-production-sales model, with R&D investment increasing from 6.9% to 21.96% of revenue from 2022 to 2024 [4] - The company emphasizes a "pyramid" R&D strategy, focusing on generic drug development at the base, modified chemical drugs and biological drugs in the middle, and innovative drug research at the top [4] Product Structure Enhancement - 泰恩康 has established three main product segments: sexual health, gastrointestinal, and ophthalmology, with core products gaining high recognition in their respective fields [4][5] - The company has several core drugs in the pipeline, including domestic first generics, expected to be approved or submitted by the end of this year to next year, which will further enhance its product structure [5]